TY - JOUR
T1 - The epidemiology of mild cognitive impairment (MCI) and Alzheimer's disease (AD) in community-living seniors
T2 - Protocol of the MemoVie cohort study, Luxembourg
AU - Perquin, Magali
AU - Schuller, Anne Marie
AU - Vaillant, Michel
AU - Diederich, Nico
AU - Bisdorff, Alexandre
AU - Leners, Jean Claude
AU - D'Incau, Marylène
AU - Ludewig, Jean Luc
AU - Hoffmann, Danielle
AU - Ulbricht, Dirk
AU - Thoma, Stephanie
AU - Dondelinger, René
AU - Heuschling, Paul
AU - Couffignal, Sophie
AU - Dartigues, Jean François
AU - Lair, Marie Lise
N1 - Funding Information:
This study was supported by the Fonds National de la Recherche (FNR) of Luxembourg. The funder had no role in the data acquisition, analyses nor the reporting of the study. The authors thank Prof. E. Bialystok for providing advice on how to measure multilingualism according to her Language and Social Background Questionnaire.
PY - 2012
Y1 - 2012
N2 - Background: Cognitive impairment and Alzheimer's disease (AD) are increasingly considered a major public health problem. The MemoVie cohort study aims to investigate the living conditions or risk factors under which the normal cognitive capacities of the senior population in Luxembourg (= 65 year-old) evolve (1) to mild cognitive impairment (MCI) - transitory non-clinical stage ' and (2) to AD. Identifying MCI and AD predictors undeniably constitutes a challenge in public health in that it would allow interventions which could protect or delay the occurrence of cognitive disorders in elderly people. In addition, the MemoVie study sets out to generate hitherto unavailable data, and a comprehensive view of the elderly population in the country. Methods/design: The study has been designed with a view to highlighting the prevalence in Luxembourg of MCI and AD in the first step of the survey, conducted among participants selected from a random sample of the general population. A prospective cohort is consequently set up in the second step, and appropriate follow-up of the non-demented participants allows improving the knowledge of the preclinical stage of MCI. Case-control designs are used for cross-sectional or retrospective comparisons between outcomes and biological or clinical factors. To ensure maximal reliability of the information collected, we decided to opt for structured face to face interviews. Besides health status, medical and family history, demographic and socio-cultural information are explored, as well as education, habitat network, social behavior, leisure and physical activities. As multilingualism is expected to challenge the cognitive alterations associated with pathological ageing, it is additionally investigated. Data relative to motor function, including balance, walk, limits of stability, history of falls and accidents are further detailed. Finally, biological examinations, including ApoE genetic polymorphism are carried out. In addition to standard blood parameters, the lipid status of the participants is subsequently determined from the fatty acid profiles in their red blood cells. The study obtained the legal and ethical authorizations. Discussion: By means of the multidisciplinary MemoVie study, new insights into the onset of cognitive impairment during aging should be put forward, much to the benefit of intervention strategies as a whole.
AB - Background: Cognitive impairment and Alzheimer's disease (AD) are increasingly considered a major public health problem. The MemoVie cohort study aims to investigate the living conditions or risk factors under which the normal cognitive capacities of the senior population in Luxembourg (= 65 year-old) evolve (1) to mild cognitive impairment (MCI) - transitory non-clinical stage ' and (2) to AD. Identifying MCI and AD predictors undeniably constitutes a challenge in public health in that it would allow interventions which could protect or delay the occurrence of cognitive disorders in elderly people. In addition, the MemoVie study sets out to generate hitherto unavailable data, and a comprehensive view of the elderly population in the country. Methods/design: The study has been designed with a view to highlighting the prevalence in Luxembourg of MCI and AD in the first step of the survey, conducted among participants selected from a random sample of the general population. A prospective cohort is consequently set up in the second step, and appropriate follow-up of the non-demented participants allows improving the knowledge of the preclinical stage of MCI. Case-control designs are used for cross-sectional or retrospective comparisons between outcomes and biological or clinical factors. To ensure maximal reliability of the information collected, we decided to opt for structured face to face interviews. Besides health status, medical and family history, demographic and socio-cultural information are explored, as well as education, habitat network, social behavior, leisure and physical activities. As multilingualism is expected to challenge the cognitive alterations associated with pathological ageing, it is additionally investigated. Data relative to motor function, including balance, walk, limits of stability, history of falls and accidents are further detailed. Finally, biological examinations, including ApoE genetic polymorphism are carried out. In addition to standard blood parameters, the lipid status of the participants is subsequently determined from the fatty acid profiles in their red blood cells. The study obtained the legal and ethical authorizations. Discussion: By means of the multidisciplinary MemoVie study, new insights into the onset of cognitive impairment during aging should be put forward, much to the benefit of intervention strategies as a whole.
KW - Aging
KW - Alzheimers disease
KW - Cognition
KW - Epidemiology
KW - Mild cognitive impairment
KW - Nested case-control cohort
KW - Population-based study
UR - http://www.scopus.com/inward/record.url?scp=84863670197&partnerID=8YFLogxK
UR - https://www.ncbi.nlm.nih.gov/pubmed/22788252
U2 - 10.1186/1471-2458-12-519
DO - 10.1186/1471-2458-12-519
M3 - Article
C2 - 22788252
AN - SCOPUS:84863670197
SN - 1471-2458
VL - 12
JO - BMC Public Health
JF - BMC Public Health
IS - 1
M1 - 519
ER -